Literature DB >> 8199959

Guidelines for control of meningococcal disease. Laboratory Centre for Disease Control. Canadian Consensus Conference on Meningococcal Disease.

.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 8199959      PMCID： PMC1337057     

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  18 in total

1.  The risk of meningitis among classroom contacts during an epidemic of meningococcal disease.

Authors:  J A Jacobson; P A Camargos; J T Ferreira; J B McCormick
Journal:  Am J Epidemiol       Date:  1976-11       Impact factor: 4.897

2.  Single-dose ceftriaxone to eradicate pharyngeal Neisseria meningitidis.

Authors:  F N Judson; J M Ehret
Journal:  Lancet       Date:  1984-12-22       Impact factor: 79.321

3.  Polysaccharide vaccines of group A Neisseria meningtitidis and Haemophilus influenzae type b: a field trial in Finland.

Authors:  P H Mäkelä; H Peltola; H Käyhty; H Jousimies; O Pettay; E Ruoslahti; A Sivonen; O V Renkonen
Journal:  J Infect Dis       Date:  1977-08       Impact factor: 5.226

4.  Epidemic meningococcal disease in an elementary-school classroom.

Authors:  R D Feigin; C J Baker; L A Herwaldt; R M Lampe; E O Mason; S E Whitney
Journal:  N Engl J Med       Date:  1982-11-11       Impact factor: 91.245

5.  Chemoprophylaxis for bacterial infections: principles of and application to meningococcal infections.

Authors:  B Schwartz
Journal:  Rev Infect Dis       Date:  1991 Jan-Feb

6.  Clinical evaluation of group A and group C meningococcal polysaccharide vaccines in infants.

Authors:  R Gold; M L Lepow; I Goldschneider; T L Draper; E C Gotschlich
Journal:  J Clin Invest       Date:  1975-12       Impact factor: 14.808

7.  Clinical efficacy of meningococcus group A capsular polysaccharide vaccine in children three months to five years of age.

Authors:  H Peltola; H Mäkelä; H Käyhty; H Jousimies; E Herva; K Hällström; A Sivonen; O V Renkonen; O Pettay; V Karanko; P Ahvonen; S Sarna
Journal:  N Engl J Med       Date:  1977-09-29       Impact factor: 91.245

8.  Immunological investigations of meningococcal disease. III. Brevity of group C acquisition prior to disease occurrence.

Authors:  E A Edwards; L F Devine; G H Sengbusch; H W Ward
Journal:  Scand J Infect Dis       Date:  1977

9.  Immunogenicity of group A and group C meningococcal polysaccharides in human infants.

Authors:  I Goldschneider; M L Lepow; E C Gotschlich; F T Mauck; F Bachl; M Randolph
Journal:  J Infect Dis       Date:  1973-12       Impact factor: 5.226

10.  Meningococcal disease in Belgium. Secondary attack rate among household, day-care nursery and pre-elementary school contacts.

Authors:  P De Wals; L Hertoghe; I Borlée-Grimée; S De Maeyer-Cleempoel; G Reginster-Haneuse; A Dachy; A Bouckaert; M F Lechat
Journal:  J Infect       Date:  1981-03       Impact factor: 6.072
View more
  3 in total

1.  Cost-benefit model comparing two alternative immunisation programmes against serogroup C meningococcal disease: for Quebec residents aged 2 months to 20 years.

Authors:  Carol Rancourt; Jean-Pierre Grégoire; W Simons; Alain Dostie
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

2.  Risk and prevention of meningococcal disease among education workers: A review.

Authors:  Philippe De Wals; Pierre Deshaies; Gaston De Serres; Bernard Duval; Lise Goulet; Bernard Pouliot; Sylvie Ricard; Maurice Poulin
Journal:  Can J Infect Dis       Date:  2004-03

3.  Estimating costs associated with a community outbreak of meningococcal disease in a colombian Caribbean city.

Authors:  Hernando Pinzón-Redondo; Wilfrido Coronell-Rodriguez; Inés Díaz-Martinez; Angel Guzmán-Corena; Dagna Constenla; Nelson Alvis-Guzmán
Journal:  J Health Popul Nutr       Date:  2014-09       Impact factor: 2.000
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.